Fabry disease program to be deprioritized, shifting focus to other clinical-stage programs in lysosomal disorder pipeline
Data updates for cystinosis and Gaucher disease type 1 programs planned for 1H 2022, with
Wedbush analyst Seth Basham reiterated an Underperform rating on the shares of Bed Bath & Beyond Inc (NASDAQ: BBBY) and lowered the price target from $5 to $1.